FdaApplication
NDA 205677
Identifiers
- fda_app_no: NDA205677
Properties
| Property | Value |
|---|---|
| applicant_name | VANDA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2014-01-31 |
Revenue by product
HETLIOZ
| Period | Revenue |
|---|---|
| Q2 2026 | $5.6M |
| Q1 2026 | $15.9M |
| Q4 2025 | $16.4M |
| Q3 2025 | $18.0M |
| Q2 2025 | $16.2M |
| Q1 2025 | $20.9M |
| Q4 2024 | $20.0M |
| Q3 2024 | $17.9M |
| Q2 2024 | $18.7M |
| Q1 2024 | $20.1M |
| Q4 2023 | $21.1M |
| Q3 2023 | $17.5M |
| Q2 2023 | $22.0M |
| Q1 2023 | $39.6M |
| Q4 2022 | $40.1M |
| Q3 2022 | $41.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| HETLIOZ | TASIMELTEON | 20MG | CAPSULE;ORAL |
1 product